丸美生物(603983):公司拟赴港上市 关注人群拓圈带来的增量潜力

Core Viewpoint - The company plans to launch an H-share listing to enhance its capital strength and overseas financing capabilities, aiming to improve overall competitiveness and accelerate international business strategy [1] Financial Performance - For the first three quarters of 2025, the company reported revenue of 2.45 billion (+25.5%) and a net profit attributable to shareholders of 244 million (+2.13%), with a non-recurring net profit of 214 million (-5.4%) [1] - In Q3 2025, revenue reached 690 million (+14.3%), net profit attributable to shareholders was 69 million (+11.6%), and non-recurring net profit was 48 million (-20%) [1] - The company corrected its H1 financial data, adjusting revenue down by 4.55 million, increasing management expenses by 10.27 million, and reducing net profit attributable to shareholders by 11.33 million [1] Profitability Metrics - Q3 2025 gross margin was 75.72% (+1.2 percentage points), with a sales expense ratio of 60.52% (+1.6 percentage points), management expense ratio of 5.89% (+1.8 percentage points), and R&D expense ratio of 3.32% (+0.2 percentage points) [1] - The net profit margin attributable to shareholders in Q3 2025 was 10.13% (-0.2 percentage points), and the non-recurring net profit margin was 7% (-3 percentage points) [1] Investment Outlook - The company is currently in a growth phase with increased expenses impacting short-term profitability, and it is essential to track the effectiveness of expanding its customer base [2] - Future focus should be on new customer conversion and the pace of profit recovery [2] - Projected net profits attributable to shareholders for 2025 and 2026 are 370 million and 460 million, respectively, corresponding to PE ratios of 36x and 29x [3]